Cargando…

Natalizumab Exerts Direct Signaling Capacity and Supports a Pro-Inflammatory Phenotype in Some Patients with Multiple Sclerosis

Natalizumab is a recombinant monoclonal antibody raised against integrin alpha-4 (CD49d). It is approved for the treatment of patients with multiple sclerosis (MS), a chronic inflammatory autoimmune disease of the CNS. While having shown high therapeutic efficacy, treatment by natalizumab has been l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Benkert, Thomas F., Dietz, Lena, Hartmann, Elena M., Leich, Ellen, Rosenwald, Andreas, Serfling, Edgar, Buttmann, Mathias, Berberich-Siebelt, Friederike
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3527399/ https://www.ncbi.nlm.nih.gov/pubmed/23284936 http://dx.doi.org/10.1371/journal.pone.0052208

Ejemplares similares

Lack of NFATc1 SUMOylation prevents autoimmunity and alloreactivity
por: Xiao, Yin, et al.
Publicado: (2020)

Follicular regulatory T cells control humoral autoimmunity via NFAT2-regulated CXCR5 expression
por: Vaeth, Martin, et al.
Publicado: (2014)

Lymphoid Aggregates in the CNS of Progressive Multiple Sclerosis Patients Lack Regulatory T Cells
por: Bell, Luisa, et al.
Publicado: (2020)

NFATc1/αA: The other Face of NFAT Factors in Lymphocytes
por: Serfling, Edgar, et al.
Publicado: (2012)

SUMOylation of the transcription factor NFATc1 leads to its subnuclear relocalization and IL2 repression by HDAC
por: Nayak, A, et al.
Publicado: (2009)

NFATc1/αA and Blimp-1 Support the Follicular and Effector Phenotype of Tregs
por: Koenig, Anika, et al.
Publicado: (2022)

NFATc1 affects mouse splenic B cell function by controlling the calcineurin–NFAT signaling network
por: Bhattacharyya, Sankar, et al.
Publicado: (2011)

Octamer-dependent transcription in T cells is mediated by NFAT and NF-κB
por: Mueller, Kerstin, et al.
Publicado: (2013)

NFATc1 induction by an intronic enhancer restricts NKT γδ cell formation
por: Giampaolo, Sabrina, et al.
Publicado: (2023)

Rapid and Efficient Gene Editing for Direct Transplantation of Naive Murine Cas9(+) T Cells
por: Majumder, Snigdha, et al.
Publicado: (2021)

The inducible transcription factor NFATc1 controls the survival of germinal center B lymphocytes
por: Serfling, E, et al.
Publicado: (2009)

Delayed and limited administration of the JAKinib tofacitinib mitigates chronic DSS-induced colitis
por: Seal, Rishav, et al.
Publicado: (2023)

T-Cell Metabolism in Graft Versus Host Disease
por: Karl, Franziska, et al.
Publicado: (2021)

Soluble VCAM-1 impairs human brain endothelial barrier integrity via integrin α-4-transduced outside-in signalling
por: Haarmann, Axel, et al.
Publicado: (2015)

Interferons and Natalizumab for Multiple Sclerosis
por: Clar, Christine, et al.
Publicado: (2008)

Natalizumab in the treatment of multiple sclerosis
por: Brown, Brandon A
Publicado: (2009)

The use of natalizumab for multiple sclerosis
por: Brandstadter, Rachel, et al.
Publicado: (2017)

Natalizumab Rebound in Multiple Sclerosis
por: Lee, Joshua D., et al.
Publicado: (2021)

Natalizumab promotes activation and pro-inflammatory differentiation of peripheral B cells in multiple sclerosis patients
por: Traub, Jan W., et al.
Publicado: (2019)

Natalizumab for the treatment of relapsing multiple sclerosis
por: Rudick, Richard A, et al.
Publicado: (2008)

The transcriptional coactivator Bob1 promotes the development of follicular T helper cells via Bcl6
por: Stauss, Dennis, et al.
Publicado: (2016)

Natalizumab in Multiple Sclerosis: Long-Term Management
por: Clerico, Marinella, et al.
Publicado: (2017)

Glioblastoma in natalizumab‐treated multiple sclerosis patients
por: Sierra Morales, Fabian, et al.
Publicado: (2017)

Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment
por: Tur, Carmen, et al.
Publicado: (2013)

The discovery of natalizumab, a potent therapeutic for multiple sclerosis
por: Steinman, Lawrence
Publicado: (2012)

Comparative efficacy of switching to natalizumab in active multiple sclerosis
por: Spelman, Timothy, et al.
Publicado: (2015)

The role of natalizumab in the treatment of multiple sclerosis: benefits and risks
por: Singer, Barry A.
Publicado: (2017)

Cognitive evolution in natalizumab-treated multiple sclerosis patients
por: Jacques, Francois H, et al.
Publicado: (2016)

Relapse-independent multiple sclerosis progression under natalizumab
por: Graf, Jonas, et al.
Publicado: (2021)

Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis
por: Callegari, Ilaria, et al.
Publicado: (2023)

Natalizumab-induced pneumonitis
por: Kaninia, Stefania, et al.
Publicado: (2021)

Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment
por: Rudelius, Martina, et al.
Publicado: (2018)

Natalizumab: A new treatment for relapsing remitting multiple sclerosis
por: Hutchinson, Michael
Publicado: (2007)

Clinical efficacy issues in the treatment of multiple sclerosis: update of natalizumab
por: Patti, Francesco, et al.
Publicado: (2009)

Unusual deterioration in a patient with multiple sclerosis on natalizumab therapy
por: Gattringer, Thomas, et al.
Publicado: (2014)

Effect of Natalizumab on Circulating CD4(+) T-Cells in Multiple Sclerosis
por: Börnsen, Lars, et al.
Publicado: (2012)

Efficacy and Side Effects of Natalizumab Therapy in Patients with Multiple Sclerosis
por: Hoepner, Robert, et al.
Publicado: (2014)

Disrupted balance of T cells under natalizumab treatment in multiple sclerosis
por: Kimura, Kimitoshi, et al.
Publicado: (2016)

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)

Natalizumab is Effective for the Treatment of Relapsing-remitting Tumefactive Multiple Sclerosis
por: Nakamura, Masataka, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_uvgg2ol17c54pjchabc8vpgg19